Idera Pharmaceuticals (NASDAQ: IDRA) posted its quarterly earnings results on Monday. The company reported ($0.24) earnings per share for the quarter.
On a related note, analysts at Piper Jaffray initiated coverage on shares of Idera Pharmaceuticals in a research note to investors on Thursday, January 3rd. They set an ?overweight? rating and a $2.00 price target on the stock.
Shares of Idera Pharmaceuticals (IDRA) opened at 0.67 on Monday. Idera Pharmaceuticals (IDRA) has a one year low of $0.65 and a one year high of $2.19. The stock?s 50-day moving average is currently $0.70. The company?s market cap is $18.5 million. Idera Pharmaceuticals, Inc. is engaged in the discovery and development of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants.